

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

MOXIEYE-LP[™] GEL

LOTEPREDNOL ETABONATE & MOXIFLOXACIN OPHTHALMIC SUSPENSION

COMPOSITION

Loteprednol Etabonate.... 0.5% w/v
Moxifloxacin Hydrochloride IP equivalent to Moxifloxacin.... 0.5% w/v
Water for Injections IP q.s.

CONTRAINDICATIONS

MOXIEYE-LP GEL is contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

MOXIEYE-LP GEL is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

MODE OF ACTION

MOXIFLOXACIN

The antibacterial action of moxifloxacin results from inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.

LOTEPREDNOL

Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

INDICATIONS AND USAGE

For the treatment of post-operative steroid responsive inflammatory ocular infections or risk of bacterial ocular infections exists. For the treatment of patients with bacterial conjunctivitis.

ADVERSE EFFECTS

MOXIFLOXACIN

Ocular hyperemia, keratoconjunctivitis sicca, abnormal sensation in eye, ocular discomfort, corneal epithelium defect, conjunctivitis haemorrhage, visual acuity reduced, eyelid edema, eye pain.

LOTEPREDNOL

Non Ocular adverse reactions occurred in less than 15% of patients. These include headache, rhinitis and pharyngitis.

DOSAGE

SHAKE VIGOROUSLY BEFORE USING.

The recommended dosage regimen for patients one year of age and older is one drop in the affected eye(s) 3 times a day.

PHARMACEUTICAL PRECAUTIONS

It is desirable that the contents should not be used for more than a month after opening container. Do not touch the dropper tip or let it touch any surface since this may contaminate the solution. If irritation persists or increases, discontinue the use and consult the doctor.

PACKING :







MOXIEYE-LP GEL solution are available in 5ml in **lyondellbasel Purell** low density polyethylene dispensing system consisting of plastic bottle with good flexibility. Tamper evidence ring around the closure and neck area of the bottle.

STORAGE INSTRUCTIONS :

Store in cool & dry place. Protect from light. Keep out of reach of children.

Use the solution within one month after opening the container.

For external use only.

INSTRUCTIONS FOR USE		
 <p>1</p>	 <p>2</p>	 <p>3</p>
Rotate cap anticlockwise to break the seal.	The vial is now ready for use; turn it up side down. Squeeze the walls of the vial gently to deliver sterile drop into the eye.	Replace the cap. Tighten it firmly and keep the vial closed for subsequent use.
 <p>4</p>	 <p>5</p>	 <p>6</p>
Do not touch the nozzle.	Do not rinse the nozzle.	Do not expose to Sunlight.
State of the art technology from Eyekare Ltd.		

Marketed by:



Division of :

Kilitch Healthcare India Ltd.

© Trade Mark applied for

Manufactured in India by:

KH KILITCH HEALTHCARE INDIA LTD.
R-904, 905, T.T.C. Industrial Area, M.I.D.C.,
Navi Mumbai, Dist. Thane, Rabale - 400 701.

EC/037/R/01